Re-expression of DIRAS3 and p53 induces apoptosis and impaired autophagy in head and neck squamous cell carcinoma

Zhe Liu; Douglas R. Hurst; Xing Qu; Li-Guang Lu; Chen-Zhou Wu; Yu-Yu Li; Yi Li

doi:10.1186/s40779-020-00275-3

Your Location：

Home >

Browse articles >

Re-expression of DIRAS3 and p53 induces apoptosis and impaired autophagy in head and neck squamous cell carcinoma

RESEARCH | Updated：2023-02-28

- Re-expression of DIRAS3 and p53 induces apoptosis and impaired autophagy in head and neck squamous cell carcinoma
- Re-expression of DIRAS3 and p53 induces apoptosis and impaired autophagy in head and neck squamous cell carcinoma
- 解放军医学杂志（英文版） 2021年8卷第2期页码：148-161
- Affiliations：
  
  1.State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
  2.Department of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
  3.Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35216, USA
  4.Department of Evidence Based Stomatology, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
- Author bio：
  
  * liyi1012@163.com
- Funds：
  
  Funding for the Basic Research of the Ministry of Sciences and Technology, Sichuan Province(2015JY0090);the National Natural Science Foundation of China(81972546;81602373)
- DOI：10.1186/s40779-020-00275-3
  中图分类号：
- 纸质出版：2021-06
- Accepted：
Scan QR Code
Re-expression of DIRAS3 and p53 induces apoptosis and impaired autophagy in head and neck squamous cell carcinoma[J]. 解放军医学杂志（英文版）, 2021,8(2):148-161.

Liu et al.: Re-expression of DIRAS3 and p53 induces apoptosis and impaired autophagy in head and neck squamous cell carcinoma. Mil Med Res, 2020, 7: 48.
Re-expression of DIRAS3 and p53 induces apoptosis and impaired autophagy in head and neck squamous cell carcinoma[J]. 解放军医学杂志（英文版）, 2021,8(2):148-161. DOI： 10.1186/s40779-020-00275-3.

Liu et al.: Re-expression of DIRAS3 and p53 induces apoptosis and impaired autophagy in head and neck squamous cell carcinoma. Mil Med Res, 2020, 7: 48. DOI： 10.1186/s40779-020-00275-3.

摘要

Abstract

Background:

p53 and DIRAS3 are tumor suppressors that are frequently silenced in tumors. In this study

we sought to determine whether the concurrent re-expression of p53 and DIRAS3 could effectively induce head and neck squamous cell carcinoma (HNSCC) cell death.

Methods:

CAL-27 and SCC-25 cells were treated with Ad-DIRAS3 and rAd-p53 to induce re-expression of DIRAS3 and p53 respectively. The effects of DIRAS3 and p53 re-expression on the growth and apoptosis of HNSCC cells were examined by TUNEL assay

flow cytometric analysis and MTT. The effects of DIRAS3 and p53 re-expression on Akt phosphorylation

oncogene expression

and the interaction of 4E-BP1 with eIF4E were determined by real-time PCR

Western blotting and immunoprecipitation analysis. The ability of DIRAS3 and p53 re-expression to induce autophagy was evaluated by transmission electron microscopy

LC3 fluorescence microscopy and Western blotting. The effects of DIRAS3 and p53 re-expression on HNSCC growth were evaluated by using an orthotopic xenograft mouse model.

Results:

TUNEL assay and flow cytometric analysis showed that the concurrent re-expression of DIRAS3 and p53 significantly induced apoptosis (

0.001). MTT and flow cytometric analysis revealed that DIRAS3 and p53 reexpression significantly inhibited proliferation and induced cell cycle arrest (

0.001). Mechanistically

the concurrent re-expression of DIRAS3 and p53 down-regulated signal transducer and activation of transcription 3 (STAT3) and upregulated p21

WAF1/CIP1

and Bax (

0.001). DIRAS3 and p53 re-expression also inhibited Akt phosphorylation

increased the interaction of eIF4E with 4E-BP1

and reduced the expression of c-Myc

cyclin D1

vascular endothelial growth factor (VEGF)

fibroblast growth factor (FGF)

epidermal growth factor receptor (EGFR) and Bcl-2 (

0.001). Moreover

the concurrent re-expression of DIRAS3 and p53 increased the percentage of cells with GFP-LC3 puncta compared with that in cells treated with control adenovirus (50.00%±4.55%

. 4.67%±1.25%

0.001). LC3 fluorescence microscopy and Western blotting further showed that DIRAS3 and p53 re-expression significantly promoted autophagic activity but also inhibited autophagic flux

resulting in overall impaired autophagy. Finally

the concurrent re-expression of DIRAS3 and p53 significantly decreased the tumor volume compared with the control group in a HNSCC xenograft mouse model [(3.12±0.75) mm

. (189.02±17.54) mm

0.001].

Conclusions:

The concurrent re-expression of DIRAS3 and p53 is a more effective approach to HNSCC treatment than current treatment strategies.

关键词

Keywords

references

McDermott JD , Bowles DW . Epidemiology of head and neck squamous cell carcinomas: impact on staging and prevention strategies . Curr Treat Options in Oncol . 2019 ; 20 ( 5 ): 43 .

Leemans CR , Braakhuis BJ , Brakenhoff RH . The molecular biology of head and neck cancer . Nat Rev Cancer . 2011 ; 11 ( 1 ): 9 - 22 .

Tassone P , Old M , Teknos TN , Pan Q . p53-based therapeutics for head and neck squamous cell carcinoma . Oral Oncol . 2013 ; 49 ( 8 ): 733 - 7 .

Philips R , Pan Q . p53 in head and neck squamous cell carcinoma . In: Warnakulasuriya S , Khan Z , editors . Squamous cell carcinoma . Dordrecht : Springer ; 2017 . p. 113 – 34 .

Lane DP , Cheok CF , Lain S . p53-based cancer therapy . Cold Spring Harb Perspect Biol . 2010 ; 2 ( 9 ): a001222 .

Zhang WW , Li L , Li D , Liu J , Li X , Li W , et al . The first approved gene therapy product for cancer ad-p53 (Gendicine): 12 years in the clinic . Hum Gene Ther . 2018 ; 29 ( 2 ): 160 - 79 .

Ma G , Shimada H , Hiroshima K , Tada Y , Suzuki N , Tagawa M . Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China . Drug Des Devel Ther . 2008 ; 2 : 115 - 22 .

Li J , Cui G , Sun L , Wang SJ , Tian S , Guan Z , et al . ARHI overexpression induces epithelial ovarian cancer cell apoptosis and excessive autophagy . Int J Gynecol Cancer . 2014 ; 24 ( 3 ): 437 - 43 .

Zou CF , Jia LQ , Jin HY , Yao M , Zhao NQ , Huan J , et al . Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel . BMC Cancer . 2011 ; 11 : 22 .

Zhang S , Feng XL , Shi L , Gong CJ , He ZJ , Wu HJ , et al . Genome-wide analysis of DNA methylation in tongue squamous cell carcinoma . Oncol Rep . 2013 ; 29 ( 5 ): 1819 - 26 .

Sutton MN , Lu Z , Li YC , Zhou Y , Huang T , Reger AS , et al . DIRAS3 (ARHI) blocks RAS/MAPK signaling by binding directly to RAS and disrupting RAS clusters . Cell Rep . 2019 ; 29 ( 11 ): 3448 - 59 .

Zhao X , Li J , Zhuo J , Cai L . Reexpression of ARHI inhibits tumor growth and angiogenesis and impairs the mTOR/VEGF pathway in hepatocellular carcinoma . Biochem Biophys Res Commun . 2010 ; 403 ( 3–4 ): 417 - 21 .

Badgwell DB , Lu Z , Le K , Gao F , Yang M , Suh GK , et al . The tumor suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/rho signaling pathways . Oncogene . 2012 ; 31 ( 1 ): 68 - 79 .

Li Y , Li B , Li CJ , Li LJ . Key points of basic theories and clinical practice in rAd-p53 (Gendicine ™) gene therapy for solid malignant tumors . Expert Opin Biol Ther . 2015 ; 15 ( 3 ): 437 - 54 .

Mizushima N , Yoshimori T . How to interpret LC3 immunoblotting . Autophagy . 2007 ; 3 ( 6 ): 542 - 5 .

Bais MV , Kukuruzinska M , Trackman PC . Orthotopic non-metastatic and metastatic oral cancer mouse models . Oral Oncol . 2015 ; 51 ( 5 ): 476 - 82 .

Tanida I , Ueno T , Kominami E . LC3 and autophagy . Methods Mol Biol . 2008 ; 445 : 77 - 88 .

Scherz-Shouval R , Weidberg H , Gonen C , Wilder S , Elazar Z , Orena M . p53-dependent regulation of autophagy protein LC3 supports cancer cell survival under prolonged starvation . Proc Natl Acad Sci U S A . 2010 ; 107 ( 43 ): 18511 - 6 .

Nichols AC , Yoo J , Palma DA , Fung K , Franklin JH , Koropatnick J , et al . Frequent mutations in TP53 and CDKN2A found by next-generation sequencing of head and neck cancer cell lines . Arch Otolaryngol Head Neck Surg . 2012 ; 138 ( 8 ): 732 - 9 .

Bykov VJN , Eriksson SE , Bianchi J , Wiman KG . Targeting mutant p53 for efficient cancer therapy . Nat Rev Cancer . 2018 ; 18 ( 2 ): 89 - 102 .

Mohammad RM , Wu J , Azmi AS , Aboukameel A , Sosin A , Wu S , et al . An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals . Mol Cancer . 2009 ; 8 : 115 .

Lu X , Qian J , Yu Y , Yang H , Li J . Expression of the tumor suppressor ARHI inhibits the growth of pancreatic cancer cells by inducing G1 cell cycle arrest . Oncol Rep . 2009 ; 22 ( 3 ): 635 - 40 .

Abraham AG , O'Neill E . PI3K/Akt-mediated regulation of p53 in cancer . Biochem Soc Trans . 2014 ; 42 ( 4 ): 798 - 803 .

Llanos S , García-Pedrero JM , Morgado-Palacin L , Rodrigo JP , Serrano M . Stabilization of p21 by mTORC1/4E-BP1 predicts clinical outcome of head and neck cancers . Nat Commun . 2016 ; 7 : 10438 .

Shamloo B , Usluer S . p21 in cancer research . Cancers . 2019 ; 11 ( 8 ): 1178 .

Dashzeveg N , Yoshida K . Cell death decision by p53 via control of the mitochondrial membrane . Cancer Lett . 2015 ; 367 ( 2 ): 108 - 12 .

Zhang H , Feng YW , Yao YM . Potential therapy strategy: targeting mitochondrial dysfunction in sepsis . Military Med Res . 2018 ; 5 : 41 .

Guo B , Cao S , Tóth K , Azrak RG , Rustum YM . Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma . Clin Cancer Res . 2000 ; 6 ( 2 ): 718 - 24 .

Yin ZJ , Jin FG , Liu TG , Fu EQ , Xie YH , Sun RL . Overexpression of STAT3 potentiates growth, survival, and radioresistance of non-small-cell lung cancer (NSCLC) cells . J Surg Res . 2011 ; 171 ( 2 ): 675 - 83 .

Martini M , De Santis MC , Braccini L , Gulluni F , Hirsch E . PI3K/AKT signaling pathway and cancer: an updated review . Ann Med . 2014 ; 46 ( 6 ): 372 - 83 .

Kaur S , Sassano A , Dolniak B , Joshi S , Majchrzak-Kita B , Baker DP , et al . Role of the Akt pathway in mRNA translation of interferon-stimulated genes . Proc Natl Acad Sci U S A . 2008 ; 105 ( 12 ): 4808 - 13 .

Takata M , Ogawa W , Kitamura T , Hino Y , Kuroda S , Kotani K , et al . Requirement for Akt (protein kinase B) in insulin-induced activation of glycogen synthase and phosphorylation of 4E-BP1 (PHAS-1) . J Biol Chem . 1999 ; 274 ( 29 ): 20611 - 8 .

Wang Z , Feng X , Molinolo AA , Martin D , Vitale-Cross L , Nohata N , et al . 4EBP1 is a tumor suppressor protein reactivated by mTOR inhibition in head and neck cancer . Cancer Res . 2019 ; 79 ( 7 ): 1438 - 50 .

Chen X , Kopecky DJ , Mihalic J , Jeffries S , Min X , Heath J , et al . Structureguided design, synthesis, and evaluation of guanine-derived inhibitors of the eIF4E mRNA-cap interaction . J Med Chem . 2012 ; 55 ( 8 ): 3837 - 51 .

Musa J , Orth MF , Dallmayer M , Baldauf M , Pardo C , Rotblat B , et al . Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): a master regulator of mRNA translation involved in tumorigenesis . Oncogene . 2016 ; 35 ( 36 ): 4675 - 88 .

Pettersson F , Del Rincon SV , Emond A , Huor B , Ngan E , Ng J , et al . Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis . Cancer Res . 2015 ; 75 ( 6 ): 1102 - 12 .

Zhou FF , Yan M , Guo GF , Wang F , Qiu HJ , Zheng FM , et al . Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells . Med Oncol . 2011 ; 28 ( 4 ): 13022 - 7 .

Yang Y , Jiang G , Zhang P , Fan J . Programmed cell death and its role in inflammation . Military Med Res . 2015 ; 2 : 12 .

Lu Z , Luo RZ , Lu Y , Zhang X , Yu Q , Khare S , et al . The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells . J Clin Invest . 2008 ; 118 ( 12 ): 3917 - 29 .

Maiuri MC , Galluzzi L , Morselli E , Kepp O , Malik SA , Kroemer G . Autophagy regulation by p53 . Curr Opin Cell Biol . 2010 ; 22 ( 2 ): 181 - 5 .

Bieging KT , Mello SS , Attardi LD . Unravelling mechanisms of p53-mediated tumour suppression . Nat Rev Cancer . 2014 ; 14 ( 5 ): 359 - 70 .

Bae EJ , Lee HJ , Jang YH , Michael S , Masliah E , Min DS , et al . Phospholipase D1 regulates autophagic flux and clearance of α-synuclein aggregates . Cell Death Differ . 2014 ; 21 ( 7 ): 1132 - 41 .

Washington MN , Suh G , Orozco AF , Sutton MN , Yang H , Wang Y , et al . ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts . Cell Death Dis . 2015 ; 6 : e1836 .

Crighton D , Wilkinson S , O'Prey J , Syed N , Smith P , Harrison PR , et al . DRAM, a p53-induced modulator of autophagy, is critical for apoptosis . Cell . 2006 ; 126 ( 1 ): 121 - 34 .

Fiorini C , Menegazzi M , Padroni C , Dando I , Dalla Pozza E , Gregorelli A , et al . Autophagy induced by p53-reactivating molecules protects pancreatic cancer cells from apoptosis . Apoptosis . 2013 ; 18 ( 3 ): 337 - 46 .

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Propofol postconditioning ameliorates hypoxia/reoxygenation induced H9c2 cell apoptosis and autophagy via upregulating forkhead transcription factors under hyperglycemia

Programmed cell death and its role in inflammation

TGF-β1 mediates hypoxia-preconditioned olfactory mucosa mesenchymal stem cells improved neural functional recovery in Parkinson’s disease models and patients

ALDH2 in autophagy and cell death: molecular mechanisms and implications for diseases

TRIM72-mediated degradation of the short form of p62/SQSTM1 rheostatically controls selective autophagy in human cells